CRDL

Cardiol Therapeutics
CRDL

$2.25

1.79%

Market Cap: 156M

About: Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Employees: 17

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 6 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

95% more capital invested

Capital invested by funds: $6.02M [Q4 2023] → $11.7M (+$5.73M) [Q1 2024]

13% more funds holding

Funds holding: 31 [Q4 2023] → 35 (+4) [Q1 2024]

0.55% less ownership

Funds ownership: 10.62% [Q4 2023] → 10.07% (-0.55%) [Q1 2024]

43% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 7

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$8

256%

upside

Avg. target

$9

300%

upside

High target

$10

344%

upside

6 analyst ratings

6 positive

100%

0 neutral

0%

0 negative

0%

Roth MKM Jason Wittes	344%upside $10	Buy Initiated	26 Jun 2024
HC Wainwright & Co. Vernon Bernardino	300%upside $9	Buy Reiterated	14 Jun 2024
HC Wainwright & Co. Vernon Bernardino	300%upside $9	Buy Reiterated	7 Jun 2024
Canaccord Genuity Edward Nash	256%upside $8	Buy Maintained	23 May 2024
HC Wainwright & Co. Vernon Bernardino	300%upside $9	Buy Reiterated	14 May 2024

See Analyst Rankings

Financial journalist opinion

Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders

Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its annual general and special meeting of shareholders (the "Meeting") held virtually via live audio webcast, on June 26, 2024. Shareholders voted in favour of all management resolutions proposed in the Company's management information circular dated May 13, 2024.

Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders

Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT

Toronto, Ontario--(Newsfile Corp. - June 25, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the Company's virtual Annual General and Special Meeting of Shareholders (the "AGM") will be webcast on June 26, 2024, at 4:30 p.m. EDT. Cardiol Therapeutics 2024 AGM When: June 26, 2024, at 4:30 p.m.

Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT

Proactive Investors

Cardiol Therapeutics releases Phase II data showing CardiolRx reduces pericarditis pain and inflammation

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) released data from its Phase II MAvERIC-Pilot study demonstrating that its lead drug candidate CardiolRx significantly reduces pericarditis pain and inflammation, showing promise as a non-immunosuppressive treatment option. The study, which assessed the efficacy of CardiolRx in treating symptomatic recurrent pericarditis, revealed a significant reduction in patient-reported pericarditis pain, the primary efficacy endpoint.

Cardiol Therapeutics releases Phase II data showing CardiolRx reduces pericarditis pain and inflammation

Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis pain CardiolRx™ also shown to reduce inflammation in patients with elevated CRP 89% of patients have continued into the extension phase of the study Toronto, Ontario--(Newsfile Corp. - June 13, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today reported 8-week clinical data from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis. The data showed a substantial reduction in the primary efficacy endpoint of patient-reported pericarditis pain at the end of the 8-week treatment period ("TP"), as well as normalization of inflammation - as measured by C-reactive protein ("CRP") - in 80% of patients with elevated CRP at baseline.

Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Zacks Investment Research

5 Small Drug Stocks to Buy From a Recovering Industry

Innovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX, BVS, AQST, ACRV and CRDL may prove to be good additions to one's portfolio.

5 Small Drug Stocks to Buy From a Recovering Industry

CRDL Stock Earnings: Cardiol Therapeutics Meets EPS for Q1 2024

Cardiol Therapeutics (NASDAQ: CRDL ) just reported results for the first quarter of 2024. Cardiol Therapeutics reported earnings per share of -10 cents.

CRDL Stock Earnings: Cardiol Therapeutics Meets EPS for Q1 2024

Proactive Investors

Cardiol Therapeutics surpasses 85% enrollment in ARCHER trial for acute myocarditis

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) showcased promising developments in its Phase II clinical trial, ARCHER, during an oral presentation at the World Congress on Acute Heart Failure 2024. The event provided a platform for Univ.

Cardiol Therapeutics surpasses 85% enrollment in ARCHER trial for acute myocarditis

Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024

Scope of presentation included trial design, rationale, and blinded baseline data on first 50 patients randomized into the Phase II study evaluating CardiolRx™ in patients with acute myocarditis ARCHER trial rationale and design also accepted for publication in the journal ESC Heart Failure ARCHER trial has now exceeded 85% of target patient enrollment MAvERIC-Pilot Phase II study investigating CardiolRx™ for recurrent pericarditis expected to report topline results in early June 2024 Toronto, Ontario--(Newsfile Corp. - May 14, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced its Phase II randomized, double-blind, placebo-controlled trial evaluating the impact of CardiolRx™ on myocardial recovery in patients with acute myocarditis ("ARCHER") was the subject of an oral presentation at the World Congress on Acute Heart Failure 2024, May 11 - 14 in Lisbon, Portugal - the annual congress of the Heart Failure Association of the European Society of Cardiology ("ESC"). The trial design, rationale, and blinded baseline data on the first 50 patients randomized into ARCHER was presented by Univ.

Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024

Proactive Investors

Cardiol Therapeutics surpasses enrolment goals, prepares for topline results

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) said it had made significant strides in 2023 and early 2024 to advance its offerings of novel therapeutic solutions to patients with underserved heart diseases. In an operational update looking at the 2023 calendar year, CEO David Elsley highlighted some of the main milestones the company achieved.

Cardiol Therapeutics surpasses enrolment goals, prepares for topline results

Proactive Investors

Cardiol Therapeutics surpasses enrollment goals, prepares for topline results

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) said it had made significant strides in 2023 and early 2024 to advance its offerings of novel therapeutic solutions to patients with underserved heart diseases. In an operational update looking at the 2023 calendar year, CEO David Elsley highlighted some of the main milestones the company achieved.

Cardiol Therapeutics surpasses enrollment goals, prepares for topline results

See News Rankings